Literature DB >> 11144469

Detection of doxorubicin cardiotoxicity by using iodine-123 BMIPP early dynamic SPECT: quantitative evaluation of early abnormality of fatty acid metabolism with the Rutland method.

K Saito1, K Takeda, S Okamoto, R Okamoto, K Makino, Y Tameda, Y Nomura, H Maeda, T Ichihara, T Nakano.   

Abstract

BACKGROUND: To evaluate the possibility of predicting the development of doxorubicin-induced cardiomyopathy, we performed quantitative assessment of the early kinetics of iodine-123 beta-methyl-iodophenyl-pentadecanoic acid (I-123 BMIPP) by means of dynamic myocardial SPECT.
METHODS: Thirty-six patients with various malignancies were examined. I-123 BMIPP dynamic myocardial SPECT was performed before chemotherapy, after chemotherapy, or both. Immediately after the injection of I-123 BMIPP (111 MBq), 30-second dynamic SPECT data were acquired successively for 15 minutes. The left ventricular (LV) myocardium was divided into 8 segments in short-axial and vertical slices. By using the time-activity curve (TAC) of each myocardial segment [Mo(t)] as an output function and the TAC of the LV cavity [B(t)] as an input function, the Rutland equation, Mo(t)/B(t)= F + K Integral of(B(t)dt/B(t)), was used as a means of assessing all segments.
RESULTS: Mo(t)/B(t) showed a good linear correlation with Integral of(B(t)dt/B(t)) from 30 seconds to 4 minutes in all 456 segments. The mean K value of 8 LV segments was significantly lower after chemotherapy than before chemotherapy (0.071+/-0.019 [n = 21] vs. 0.095+/-0.025 [n = 36], P<.001). In 21 patients in whom dynamic SPECT was performed both before and after chemotherapy, the mean K values of left ventricle showed a significant decrease, from 0.101+/-0.024 to 0.071 +/-0.019 (P<.0001). The fractional change in the value of K after chemotherapy showed a significant linear correlation with the administered dose of doxorubicin (r = 0.648, P<.002).
CONCLUSION: I-123 BMIPP dynamic myocardial SPECT may be clinically useful, because it permits the early detection of doxorubicin-induced cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11144469     DOI: 10.1067/mnc.2000.108351

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  31 in total

1.  Myocardial accumulation of iodinated beta-methyl-branched fatty acid analogue, iodine-125-15-(p-iodophenyl)-3-(R,S)methylpentadecanoic acid (BMIPP), in relation to ATP concentration.

Authors:  Y Fujibayashi; Y Yonekura; Y Takemura; K Wada; K Matsumoto; N Tamaki; K Yamamoto; J Konishi; A Yokoyama
Journal:  J Nucl Med       Date:  1990-11       Impact factor: 10.057

Review 2.  The cardiotoxicity of chemotherapeutic drugs.

Authors:  A Allen
Journal:  Semin Oncol       Date:  1992-10       Impact factor: 4.929

3.  Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer.

Authors:  M Estorch; I Carrió; L Berná; C Martínez-Duncker; C Alonso; J R Germá; B Ojeda
Journal:  J Nucl Med       Date:  1990-12       Impact factor: 10.057

4.  Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT.

Authors:  T Ichihara; K Ogawa; N Motomura; A Kubo; S Hashimoto
Journal:  J Nucl Med       Date:  1993-12       Impact factor: 10.057

5.  Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity.

Authors:  C L Maini; R Sciuto; A Ferraironi; P Vici; A Tofani; A Festa; F Conti; M Lopez
Journal:  J Nucl Cardiol       Date:  1997 Nov-Dec       Impact factor: 5.952

6.  Evaluation of myocardial viability with iodine-123-BMIPP in a canine model.

Authors:  R Nohara; K Okuda; M Ogino; R Hosokawa; N Tamaki; J Konishi; Y Fujibayashi; Y Yonekura; M Fujita; S Sasayama
Journal:  J Nucl Med       Date:  1996-08       Impact factor: 10.057

7.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

8.  Absent myocardial iodine-123-BMIPP uptake and platelet/monocyte CD36 deficiency.

Authors:  E H Hwang; J Taki; S Yasue; M Fujimoto; M Taniguchi; I Matsunari; K Nakajima; S Shiobara; T Ikeda; N Tonami
Journal:  J Nucl Med       Date:  1998-10       Impact factor: 10.057

9.  Anthracycline cardiomyopathy monitored by morphologic changes.

Authors:  M E Billingham; J W Mason; M R Bristow; J R Daniels
Journal:  Cancer Treat Rep       Date:  1978-06

10.  Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.

Authors:  M R Bristow; J W Mason; M E Billingham; J R Daniels
Journal:  Am Heart J       Date:  1981-10       Impact factor: 4.749

View more
  10 in total

1.  Collimator choice in cardiac SPECT with I-123-labeled tracers.

Authors:  Yusuke Inoue; Ichiro Shirouzu; Toru Machida; Yasunori Yoshizawa; Fumihide Akita; Manabu Minami; Kuni Ohtomo
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

2.  Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study.

Authors:  Hein J Verberne; Christel Feenstra; W Matthijs de Jong; G Aernout Somsen; Berthe L F van Eck-Smit; Ellinor Busemann Sokole
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-18       Impact factor: 9.236

Review 3.  Noninvasive imaging of cardiovascular injury related to the treatment of cancer.

Authors:  Suwat Kongbundansuk; W Gregory Hundley
Journal:  JACC Cardiovasc Imaging       Date:  2014-08

4.  Effectiveness of Iodine-123 β-methyl-P-iodophenyl-pentadecanoic acid (BMIPP) Myocardial Scintigraphy for Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD) in Breast Cancer Patients.

Authors:  Yuko Harada; Kyosuke Shimada; Yukino Kubota; Miyoko Yamashita
Journal:  Cureus       Date:  2022-05-31

5.  Effect of collimator choice on quantitative assessment of cardiac iodine 123 MIBG uptake.

Authors:  Yusuke Inoue; Akira Suzuki; Ichiro Shirouzu; Toru Machida; Yasunori Yoshizawa; Fumihide Akita; Satoshi Ohnishi; Kohki Yoshikawa; Kuni Ohtomo
Journal:  J Nucl Cardiol       Date:  2003 Nov-Dec       Impact factor: 5.952

6.  Mitochondrials complex I activity is reduced in latent adriamycin-induced cardiomyopathy of rat.

Authors:  Kiyotaka Ohkura; Jong-Dae Lee; Hiromasa Shimizu; Akira Nakano; Hiroyasu Uzui; Motosaburo Horikoshi; Yasuhisa Fujibayashi; Yoshiharu Yonekura; Takanori Ueda
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

Review 7.  Nuclear imaging in detection and monitoring of cardiotoxicity.

Authors:  Carmen D'Amore; Paola Gargiulo; Stefania Paolillo; Angela Maria Pellegrino; Tiziana Formisano; Antonio Mariniello; Giuseppe Della Ratta; Elisabetta Iardino; Marianna D'Amato; Lucia La Mura; Irma Fabiani; Flavia Fusco; Pasquale Perrone Filardi
Journal:  World J Radiol       Date:  2014-07-28

8.  In Vivo Reactive Oxygen Species Detection With a Novel Positron Emission Tomography Tracer, 18F-DHMT, Allows for Early Detection of Anthracycline-Induced Cardiotoxicity in Rodents.

Authors:  Nabil E Boutagy; Jing Wu; Zhengxi Cai; Wenjie Zhang; Carmen J Booth; Tassos C Kyriakides; Daniel Pfau; Tim Mulnix; Zhao Liu; Edward J Miller; Lawrence H Young; Richard E Carson; Yiyun Huang; Chi Liu; Albert J Sinusas
Journal:  JACC Basic Transl Sci       Date:  2018-05-30

9.  Computed Tomographic Angiography Assessment of Epicardial Coronary Vasoreactivity for Early Detection of Doxorubicin-Induced Cardiotoxicity.

Authors:  Attila Feher; Nabil E Boutagy; John C Stendahl; Christi Hawley; Nicole Guerrera; Carmen J Booth; Eva Romito; Steven Wilson; Chi Liu; Albert J Sinusas
Journal:  JACC CardioOncol       Date:  2020-06-16

Review 10.  New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging.

Authors:  Farah Cadour; Franck Thuny; Joevin Sourdon
Journal:  Front Cardiovasc Med       Date:  2022-02-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.